Product logins

Find logins to all Clarivate products below.


DRG Fingertip Foundations

Pharmacist validated market access intelligence delivering coverage, restrictions, transparent policy sourcing, and policy change tracking.

Pharmacist-validated, AI-powered market access intelligence

Arming market access, forecasting, and commercial teams with actionable coverage, restriction, and policy intelligence across medical and pharmacy benefits—delivering a reliable foundation for access planning and execution.

Play video

Drive better payer engagement with actionable coverage clarity

Pharmacist‑validated coverage and policy intelligence sourced directly from health plans — giving your teams the confidence to plan faster, respond sooner, and execute with precision.

Reveal real-world accessbarriers

Identify real world access barriers with pharmacist validated coverage and restriction intelligence—so you can prioritize accounts, validate assumptions, and support payer strategy with confidence.

Turn policy into forecasting insight

Translate complex payer medical policies into standardized, analyst ready business rules that strengthen access assumptions and launch forecasts.

See your competitive position clearly

Compare policy criteria, restrictions, and benefit design across payers to reveal competitive strengths, uncover hidden hurdles, and fine‑tune your negotiation strategy.

Optimize access and payer strategy

Get coverage and restriction level clarity on medical and pharmacy benefits including prior authorization logic, step edits, sub indication criteria, and utilization management rules —empowering teams to anticipate restrictions, engage payers confidently, and prioritize access opportunities with clarity.

Foundational market access intelligence you can trust - validated by experts

The industry’s most accurate pharmacist validated coverage, restriction, and policy intelligence—built to support confident access decisions.

Fingertip coverage

Track real-world formulary coverage across medical and pharmacy benefit types, organized by plan, therapeutic area, and product to gain rapid visibility into your brand.

Fingertip coverage

Fingertip restrictions

Reveal the restriction details that define access—prior authorization logic, step edits, sub indication criteria, and full coverage requirements—so you can see the true path to patient access.

Fingertip restrictions

Fingertip publisher

Access complete policy documents—linked PDFs and structured metadata—showing exactly how payers define coverage, ensuring full transparency and compliance.

Fingertip publisher

Fingertip PolicyTrack

Monitor payer policy changes over time with clear versioning and change alerts to support brand tracking and competitive monitoring.

Fingertip PolicyTrack

Get trusted access clarity

Get definitive, pharmacist‑validated coverage and policy insights for your brand.

Questions we help you answer with confidence

Foundational market access questions teams must answer before strategy and execution.

  • How is my brand covered compared to my competitors and what restrictions exist preventing access?
  • How can I validate payer coverage assumptions to deliver credible forecasts that drive confident launch planning?
  • How can I interpret payer medical policies to understand their impact on uptake and build actionable rules for forecasting and launch?

Why DRG Fingertip Foundations?

20+
years of market access expertise
15+ years
of coverage, and policy data, spanning 35K drugs
50+
analyst team with geographic & industry expertise

Resources

Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
Blog March 26, 2026
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs

Our recent webinar on Drugs to Watch 2026: Navigating the next wave of GLP-1 evolution and beyond drew some excellent audience questions. Expert Clarivate analysts Carles Recasens and Shambhavi Shukla…

Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers

Everyone wins when a provider-administered drug can be given less often or requires less time in the chair. Patients value fewer needle sticks and more free time. Busy health systems…

The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?

This blog post is the last in our series about the Complete Response Letters (CRLs) that the U.S. Food and Drug Administration (FDA) issued to Sanofi for tolebrutinib to treat…

Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar

This blog post is the third in our series about the Complete Response Letters (CRLs) that the U.S. Food and Drug Administration (FDA) issued to Sanofi for tolebrutinib to treat…

Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals

This blog post is the second in our series about the Complete Response Letters (CRLs) that the U.S. Food and Drug Administration (FDA) issued to Sanofi for tolebrutinib to treat…

chevron_left
chevron_right

Frequently asked questions

Market access coverage and restriction data describes how therapies are covered across medical and pharmacy benefits, including formulary status, prior authorization requirements, step edits, and policy criteria. This data helps teams understand real world access conditions and validate assumptions used in forecasting and payer strategy.

Fingertip combines AI‑powered extraction with clinical pharmacist validation and links every insight back to the original policy source for full transparency. The platform continuously refreshes data across 4,800+ formularies and 900+ payers, supported by more than 10 years of longitudinal data.

Policy changes are scraped and versioned across 950+ payer and plan types, with weekly email alerts highlighting new or updated policies. Teams can filter alerts by payer, book of business, document type, or update type to focus only on what matters.

Yes. Fingertip provides payer‑validated, sub‑indication‑level criteria, which can be translated into defensible business rules for forecast models. This helps teams reduce manual validation time, strengthen assumptions, and improve cross‑functional confidence in projections.

Yes. Fingertip insights can be tailored by indication, geography, benefit type, or internal taxonomy, and delivered via APIs, bridge files, or modular tools to fit your reporting, analytics, or field‑execution workflow.

Explore our market access solutions

Bring treatments to patients faster.

DRG Fusion

Ignite commercial success in life sciences and healthcare with a modular analytics product powered by real-world data

Healthcare Business Insights

Our mission is to provide healthcare insights that change lives

DRG Fingertip Insights Reports

Unlock hyper-local and hyper-targeted assessments of patient populations, markets and treatment influencers to guide you through the evolving complexities of the global reimbursement markets.